Introduction:Brentuximab vedotin (Bv) is increasingly being used for the treatment of CD30+ lymphomas, being Bv-induced peripheral neurotoxicity (BvPN) one of the greatest concerns for treating physicians. The mechanisms of BvPN are still partially known, and currently, no biomarker to predict this side effect and its severity is available. Neurofilament (NfL) is a neuron specific protein; high levels can be detected in peripheral blood with ongoing neuronal damage. It can be useful to quantify the extend of chemotherapy induced peripheral neurotoxicity due to axonal injury but its role in early detecting and predicting severity of BvPN is unknown. The objective of this study is to determine the association between pNfL and BvPN in lymphoma patients receiving Bv.